RBC Capital analyst Luca Issi maintained a Buy rating on Arrowhead Pharmaceuticals (ARWR – Research Report) yesterday and set a price target of ...

Eli Lilly topped the list of the 20 biggest pharmas by market cap with a more than 39% improvement year-to-date in its share ...

Novo Nordisk announced today that Wegovy® (semaglutide injection) is now approved to reduce the risk of non-fatal myocardial infarction in adults with established cardiovascular disease and ...

CAMBRIDGE, Mass., November 27, 2024--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that management will present a company ...

New guidance from health technology assessment (HTA) agency NICE backs the use of Wainzua (eplontersen) to treat stage 1 or 2 ...

Algert Global LLC increased its holdings in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY – Free Report) by 401.3% ...

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY – Free Report) – Investment analysts at Zacks Research increased their FY2024 ...

Canaccord Genuity analyst Whitney Ijem maintained a Buy rating on Alnylam Pharma (ALNY – Research Report) yesterday and set a price target of ...

KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), today announced that Laurence Reid, Ph.D., has been appointed to the Company’s ...

Delving into the details, we found 5% of traders were bullish, while 84% showed bearish tendencies. Out of all the trades we spotted, 14 were puts, with a value of $931,387, and 5 were calls, valued ...

The FDA has accepted Alnylam’s supplemental New Drug Application for Amvuttra on the heels of BridgeBio’s Attruby nod, ...

On a Zoom call last month from California, BridgeBio CEO Neil Kumar needled a colleague about the remote possibility of the ...